XELJANZ is the first and only oral JAK inhibitor approved for adults with moderate to severe RA, active PsA, and pediatric patients with active pcJIA1

XELJANZ® (tofacitinib) Oral Solution is anticipated to be available by the end of Q1 of 2021. XELJANZ 5 mg tablets are available immediately for patients ≥40 kg.2

Pfizer announces the FDA approval of XELJANZ for the treatment of active pcJIA in patients 2 years of age and older1

See press release

See full Prescribing Information for XELJANZ

Learn more

Assisting with access and affordability for patients prescribed XELJANZ

Start now
Patients with active polyarthritis, including RF negative, RF positive, extended oligoarthritis, systemic JIA without systemic manifestations, as well as JPsA and ERA, were enrolled in XELJANZ Study pcJIA-I.1
ERA=enthesitis-related arthritis; FDA=US Food and Drug Administration; JAK=Janus kinase; JIA=juvenile idiopathic arthritis; JPsA=juvenile psoriatic arthritis; pcJIA=polyarticular course juvenile idiopathic arthritis; PsA=psoriatic arthritis; RA=rheumatoid arthritis; RF=rheumatoid factor; UC=ulcerative colitis.

Register

Receive updates, resources, and more on XELJANZ and other Pfizer products

Explore now

References:

  1. XELJANZ [prescribing information]. New York, NY: Pfizer Inc., October 2020.
  2. Data on file. Pfizer Inc., New York, NY.